CellaVision AB

As of June 30, 2026, CellaVision AB carries a market capitalization of 293.37M, placing it among publicly traded companies globally. Its enterprise value stands at 282.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CellaVision AB's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, CellaVision AB has 23.85M shares outstanding.

As of June 30, 2026, CellaVision AB trades at a trailing price-to-earnings ratio of 25.17. The price-to-sales ratio is 4.40, and the price-to-book ratio stands at 3.67.

As of June 30, 2026, CellaVision AB trades at an EV/EBITDA multiple of 19.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. CellaVision AB trades at an EV/FCF ratio of 17.94, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 282.55M versus a market cap of 293.37M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CellaVision AB maintains a current ratio of 3.31, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.90, indicating elevated leverage, while an interest coverage ratio of 68.45 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, CellaVision AB posted a return on equity (ROE) of 15.11, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 14.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 11.79, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 14.62, useful for judging operating efficiency across full business cycles. The company generates approximately 269,898.22 in revenue per employee across its workforce of 247.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.89 indicates how many times CellaVision AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, CellaVision AB recorded 3.09M in income tax expense. That works out to an effective tax rate of 20.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 14.75M, leaving 11.65M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, CellaVision AB's stock has declined approximately 11.48% over the past 52 weeks. The 50-day moving average sits at 15.05, while the 200-day moving average is 13.65.

Over the twelve months ended June 30, 2026, CellaVision AB generated 66.73M in revenue and converted that into 11.65M in net income, yielding earnings per share of 0.49. EBITDA reached 14.84M, while operating income came in at 14.84M.

As of June 30, 2026, CellaVision AB holds 15.55M in cash and equivalents against 4.72M in total debt, resulting in a net debt position of -10.83M. Total book value stands at 79.98M, with working capital of 27.55M providing operational flexibility.

CellaVision AB produced 15.58M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, CellaVision AB posted a gross margin of 68.71, reflecting its pricing power and cost economics. The operating margin of 22.23 and net profit margin of 17.46 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, CellaVision AB paid dividends of 0.25 per share. The dividend payout ratio of 50.81 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 5.31, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to CellaVision AB shareholders.